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Type III Hyperlipoproteinemia and Spontaneous Atherosclerosis in Mice
































To study isoform-specific effects of apolipoprotein E (apoE)









 gene via targeted gene replacement
in embryonic stem cells. Mice expressing human apoE2 (2/2)
have virtually all the characteristics of type III hyperlipo-
proteinemia. Their plasma cholesterol and triglyceride lev-
els are both twice to three times those in (normolipidemic)
mice that are expressing human apoE3 (3/3) made in an





-migrating VLDL particles, and spontaneously
develop atherosclerotic plaques, even on a regular diet. An
atherogenic diet, high in fat and cholesterol, exacerbates de-
velopment of atherosclerosis and xanthomas in the 2/2 mice.
Thus, comparisons between the 2/2 and 3/3 mice unequivo-
cally demonstrate that a single amino acid difference
(Arg158 Cys) in the apoE protein is sufficient to cause type


































 is characterized by ac-





-VLDL, which results in elevated plasma levels of to-
tal cholesterol (TC) and triglycerides (TG). Type III HLP oc-
curs in 1 in 1,000–5,000 individuals, and if untreated will cause
a large percentage of patients to develop xanthomas and pre-
mature atherosclerosis (1). The primary molecular cause of the
disease is the presence of a dysfunctional form of apolipopro-
tein (apo) E, a critical ligand needed for plasma lipoprotein
clearance. The majority of type III HLP individuals are ho-
mozygous for the apoE2 isoform, although in rare instances
dominant apoE mutations are associated with the disease.
ApoE2 differs from the most common isoform, apoE3, by only
a single amino acid substitution, cysteine at position 158 in





1% of apoE3 in vitro (2). The majority of apoE2
homozygotes have below average plasma cholesterol levels,
but 5–10% of homozygotes develop type III HLP. Thus, addi-
tional genetic, hormonal, or environmental factors are re-
quired to precipitate the disease (3).
In previous attempts to uncover the elusive precipitating
factor(s) and to model type III HLP, transgenic animals have
been generated by pronuclear injection of DNA expressing ei-
ther one of the rare dominant forms of apoE (4, 5) or the
apoE2 isoform (6–9). These animals have some of the charac-
teristics of type III HLP, but rigorous comparisons to other
transgenic mice expressing the common human apoE3 isoform
are not possible because the transgenes were inserted into the
genome in different copy numbers and in different chromo-
somal locations. For example, transgenic mice expressing low
levels of human apoE2 are hypolipidemic, while those express-
ing high levels are hyperlipidemic (7). Additionally, the pres-
ence of endogenous mouse apoE protein in some cases com-
plicates the interpretation of the phenotype.
We have previously reported the use of a gene replacement









 gene, and have demonstrated that
these mice express human apoE3 transcripts in a tissue-specific
and physiological manner (10). Here we report generating









 gene using the same procedure, and the use of















 allele was performed in
mouse embryonic stem cells using the same strategy as previously de-









. All the 2/2 and 3/3 mice used in this
study were 129/C57BL/6 F2 generation hybrids. The 2/3 heterozy-
gotes were F3 generation mice derived from mating 2/2 and 3/3 ani-
mals. Animals were maintained on regular chow containing 4.5%
fat and 0.022% cholesterol (Prolab Isopro Rat/Mouse/Hamster
3000[5P76]; Agway Inc., Syracuse, NY), or were fed an atherogenic
diet that contains 15.8% (wt/wt) fat, 1.25% (wt/wt) cholesterol, and
0.5% (wt/wt) sodium cholate (TD 88051; Harlan Teklad, Madison,
WI) or a western-style diet containing 21% fat and 0.2% cholesterol
(TD 88137; Harlan Teklad). The animals were handled under proto-
cols approved by the institutional animal care and use committees.
 
Plasma lipid and lipoprotein analysis. 
 












l of plasma was electrophoresed in precast 1%
agarose gels (Ciba Corning Diagnostics Corp., Palo Alto, CA), and
neutral lipids were visualized by Fat Red 7B staining (Sigma Chem-




l) from either individual or
pooled samples was separated by gel filtration chromatography using
a Superose 6 HR10/30 column (Pharmacia LKB Biotechnology, Inc.,
Piscataway, NJ). Fractions (0.5 ml) were collected at a flow rate of 0.4
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 Abbreviations used in this paper:
 
 apo, apolipoprotein; FPLC, fast
protein liquid chromatography; HLP, hyperlipoproteinemia; IDL, in-
termediate density lipoprotein; TC, total cholesterol; TG, triglyceride.
 
 




ml/min. Cholesterol, free cholesterol, HDL-cholesterol, and TG were
measured using enzymatic kits (Cholesterol CII, Free cholesterol C;
Wako Bioproducts, Richmond, VA; Triglyceride [GPO-Triender];
Sigma Chemical Co.), and ApoE was measured using an ELISA with









of whole plasma was performed according to the method of
Hackler et al. (11). SDS-PAGE and agarose gel immunoblot analyses
were as described (10). Clofibrate (Atromid-S; Wyeth-Ayerst, New


























72% of the tracer
as cholesterol ester, was isolated 36 h later by centrifugation at a den-













-VLDL, and serum samples were obtained at intervals up to 2 h.
The fractional catabolic rates and their variances were determined as
described previously (12) using a two-compartment model. Male




Segments of the proximal aorta and aortic
sinus were embedded, sectioned, and stained as described (13). Mor-
phometric measurements of the atherosclerotic lesion area for each




 The significance of differences between means













Plasma lipids in mice fed normal chow. 
 
Isoelectric focusing of


















 (3/3) shows that the mice are producing human
apoE2 and apoE3 isoforms indistinguishable from those




). However, the 2/2 mice ex-
hibit plasma lipid and lipoprotein profiles strikingly different
from the profiles of 3/3 mice. Thus, plasma TC and TG levels
in the 2/2 mice are two to three times higher than those in the






0.0001). Animals of both sexes are equally affected, and
plasma lipid levels are elevated at 2 mo of age and remain sta-
ble for over 1 yr. The HDL cholesterol levels in the 2/2 and 3/3
mice were not different. The plasma lipid levels in 2/3 het-
erozygotes are normal (Table I), demonstrating that, as in hu-
mans, homozygosity of the apoE2 allele is needed to cause the
hyperlipidemic phenotype. However, unlike humans in which
apoE2 homozygosity is necessary but not sufficient to cause
type III HLP, all the 2/2 mice, regardless of gender and age,
develop hyperlipidemia, even on a low-fat and low-cholesterol
diet. Thus, our findings suggest that the factor(s) responsible




 are already present in mice.
 
Distribution of lipids and lipoproteins. 
 
Type III HLP has
been described as broad-beta disease (14) because of the char-




-VLDL on agarose gel electro-














); in contrast, 3/3 plasma shows virtually no








-VLDL particles from the 2/2





1% in 3/3 mice), and have a VLDL cholesterol-










-VLDL in 2/2 plasma is further illustrated





65% of the total cholesterol is in lipoproteins that elute
in the VLDL-intermediate density lipoprotein (IDL) range








85% of the choles-
terol in the 3/3 mice is in the HDL range (fractions 27–31). The
majority of TG in both groups of mice is in the VLDL fraction,
although the TG levels in the 2/2 mice are much higher than in
the 3/3 mice.
Plasma apoE2 levels in the 2/2 mice were 16-fold higher
than apoE3 levels in the 3/3 mice (Table I). ApoE2 was associ-
ated with lipoproteins in the VLDL-IDL range, and appeared
as two distinct peaks (fractions 15 and 20) by FPLC analysis.
SDS-PAGE of lipoproteins fractionated by sequential density
ultracentrifugation of plasma from the 2/2 mice agreed with
the FPLC analysis in showing that the majority of apoE2 was
Figure 1. Type III HLP in the 2/2 mice. (A) Detection of human 
apoE isoforms in plasma. Delipidated plasma samples from 2/2, 2/3, 
and 3/3 mice were separated by isoelectric focusing, and the apoE 
proteins were visualized by silver staining after immunofixation with 
an antihuman apoE antibody (10). The positions of the human apoE 
isoforms—E2 and E3—are indicated. A plasma sample from a human 
heterozygote APOE*2/APOE*3 (hu2/3) was used as a control. (B)
b-VLDL migration in an agarose gel. Whole plasma (Plasma) or the 
d , 1.006 g/ml fraction (1.006) isolated by density ultracentrifugation 
was electrophoresed in a 1% agarose gel and stained with Fat Red 
7B. The positions of the origin (o), a, b, and pre-b lipoproteins are in-
dicated. (C) Distribution of plasma lipoproteins and apoE. Pooled 
plasma (100 ml) from ten 3/3 and ten 2/2 mice fed normal chow, and 
that from three 2/2 mice fed chow containing 0.5% clofibrate (wt/wt) 
for 6 d were fractionated by FPLC (Pharmacia LKB Biotechnology, 
Inc.). Cholesterol (TC), triglycerides (TG), and ApoE content of 















(high plasma levels of apoE2 with the majority of apoE in rem-
nant lipoprotein particles is another hallmark of type III HLP
[16]). SDS-PAGE also revealed that both the ApoB100 and
apoB48 amounts in 2/2 plasma were increased two- and eight-
fold, respectively, compared with the 3/3 mice. ApoB48 was in-
creased equally in both VLDL and IDL-LDL fractions, while
the increase in apoB100 was mainly in the VLDL fraction. The
amount of apoB100 in the LDL fraction of 2/2 mice was simi-
lar to that in the 3/3 mice (data not shown).
 
Response to clofibrate treatment. 
 
Plasma lipid levels in
type III HLP patients are usually responsive to lipid-lowering
drugs such as fibric acid derivatives like clofibrate (17, 18).
Treatment of the 2/2 mice with clofibrate (0.5%, wt/wt in
chow) for 6 d altered their plasma lipid profiles dramatically in
three out of four animals. The reason for the absence of
change in one of the four animals is not currently known, but
may be related to its genetic background since the tested ani-
mals were from the F2 generation. In the three animals that re-
sponded, mean plasma TG levels decreased from elevated



















marked decrease in cholesterol and TG in the larger lipopro-
teins (VLDL-IDL range), while HDL cholesterol was in-
creased. The lipoproteins in the HDL range were larger as
judged by a shift in the HDL cholesterol peak. These alter-
ations in plasma lipoprotein profiles after clofibrate treatment
are again very similar to what has been observed in human pa-
tients treated with fibrates (19).
 
Delayed clearance of VLDL and spontaneous atherosclero-
sis. 
 





the 2/2 mice is the result of impaired clearance of the larger li-













 mice into the circulation of 2/2 mice.




50% of the labeled particles remained in the
circulation in the 2/2 mice after 2 h, as was also found when








 mice. In contrast, virtu-
ally all the label was cleared from the circulation in the 3/3
mice within 2 h (Fig. 2). The observed fractional catabolic rate








 mice, and 0.02/min in the 3/3 mice. These results show
that the 2/2 mice have a severe defect in clearing larger lipo-
proteins, in agreement with the observations by van Vlijmen et




transgenic mice lacking endogenous apoE










their residence time in blood, and would be expected to in-
crease their atherogenicity. In confirmation of this expecta-
tion, we found atherosclerotic plaques in the proximal aorta of
10-mo-old female 2/2 mice maintained on regular chow. All
seven 2/2 females evaluated had plaques near the aortic root,












































 shows a representative
section with plaques composed mainly of foam cells and some

















), typically an accumulation of several foam
cells, were found in only 4 of 11 female 3/3 mice aged 10–12
 
Table I. Plasma Lipids and apoE Concentration
 
Gender Genotype Diet TC TG HDL-c apoE
 
mg/dl (n) mg/dl (n) mg/dl (n) mg/dl (n)
 










619 (15) 2165 (12)
HFC 12976311 (9) 40616 (9) 1065 (9) 43610 (9)
2/3 ND 81610 (5) 54616 (5) 4366 (3) —
3/3 ND 75615 (11) 48613 (10) 52615 (7) 1.360.5 (10)
HFC 2976148 (9) 29611 (9) 22613 (7) 1165 (5)
Males 2/2 ND 201638 (18) 201687 (16) 53618 (18) 2069 (4)
HFW 595658 (4) 231641 (4) 53635 (4) 42636 (2)
2/3 ND 91618 (4) 5066 (4) 6767 (3) —
3/3 ND 102651 (4) 6466 (3) 75641 (4) 1.260.7 (4)
HFW 172666 (4) 64617 (4) 91637 (4) 462.5 (4)
Data are means6SD in mg/dl of mice receiving a normal chow diet (ND), a western type diet (HFW), or an atherogenic diet (HFC). Lipid levels of
HFW-fed mice were measured 4 wk after a 6-h fast. Mice on a ND and mice fed the HFC diet for 8 wk were measured after a 16-h fast. TC, total cho-
lesterol; TG, tryglycerides.
Figure 2. The plasma 
clearance of labeled 
apoE-deficient remnant 
particles. Three each of 
2/2, 2/2, and 3/3 mice 
were injected with radio-
labeled apoE 2/2 rem-
nant particles, and the 
label remaining in the 
plasma was measured 
for over 2 h. Values 
(mean radioactivity




except in 2/2 and 2/2 
groups at 120 min.
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mo. No plaques were seen in wild-type (1/1) mice of the
same age.
Response to high-fat diets. When male 2/2 mice were
placed on a western-style diet containing 21% fat and 0.2%
cholesterol, their plasma TC levels tripled (P , 0.001), accom-
panied by a slight but not statistically significant increase
in TG, and no change in HDL cholesterol (Table I). On an
atherogenic diet that contains 15.8% fat, 1.25% cholesterol,
and 0.5% sodium cholate, female 2/2 mice responded with a
fivefold increase in plasma TC (P , 0.001), while their TG and
HDL cholesterol levels were significantly reduced (P , 0.001,
Table I). The different responses of the TG and HDL levels
between the two groups is most likely due to diets rather than
to their sexes, although the mechanisms for these responses
are not known. Control (3/3) mice responded to the respective
diets similarly to the 2/2 mice, but to lesser degrees.
Feeding the atherogenic diet for 3 mo enhanced plaque
development in the female 2/2 mice (mean size, 5.3 3 105 mm2,
n 5 9); and the plaques were eight times larger than those
found in the 3/3 female mice (6.4 3 104 mm2, n 5 6) on the
same diet. Although the lesions in the 2/2 mice consisted
chiefly of foam cells, many also had fibrous caps, cholesterol
clefts, and necrotic cores (Fig. 3 B). In contrast, the lesions in
the 3/3 mice consisted solely of foam cells (Fig. 3 C). Thus, a
diet high in fat and cholesterol exacerbates the hyperlipidemia
as well as development of atherosclerosis in the 2/2 animals.
Another distinguishing characteristic of patients with type
III HLP is the presence of planar and dermal xanthomas (20,
21). The atherogenic diet caused swelling of the carpi, paws,
and periorbital area, and a dramatic deposition of lipid under-
neath the skin in the 2/2 mice. Histological examination of the
skin showed numerous foam cells, cholesterol clefts, and neu-
trophils in the hypodermis (Fig. 3 D). Lipid-laden macro-
phages were abundantly present in other tissues such as the fa-
cial plane of skeletal muscle, submucosa of the esophagus, and
the lymph nodes.
Feeding an atherogenic diet to wild-type mice long-term
causes severe fatty changes in their livers (22). The livers of 2/2
mice on the atherogenic diet, however, appeared relatively
normal on gross examination, while the wild-type livers were
enlarged and pale. Histologically, the 2/2 livers had many lipid-
laden cells (presumably Kupffer cells) in the sinusoidal spaces
surrounding hepatocytes with essentially normal appearance
(Fig. 3 E). In marked contrast, the hepatocytes in the wild-type
livers were enlarged with microvesicular lipid deposits, and the
numbers of anucleate and binucleate hepatocytes were in-
creased (Fig. 3 F). These changes and their differences be-
tween the 2/2 and the 3/3 mice suggest that the apoE2 is an in-
effective ligand for removing lipoproteins via hepatocellular
lipoprotein receptors, thereby protecting hepatocytes from
fatty changes while accelerating lipoprotein uptake by a de-
fault pathway that likely involves macrophages and Kupffer
cells.
Discussion
The data presented here clearly demonstrate that production
at a physiological level of the human apoE2 isoform, but not of
the apoE3 isoform, is sufficient to cause type III HLP and
spontaneous atherosclerosis in mice. Virtually all the charac-
teristics of the type III HLP seen in humans are present in the
2/2 mice. These include a two- to threefold elevation in the
plasma levels of TC and TG, a VLDL cholesterol-to-triglycer-
ide ratio . 0.3, broad migration of b-VLDL in agarose gel
electrophoresis, and abnormally high plasma levels of apoE2
with the majority of the apoE2 being in remnant lipoprotein
particles. Diets high in fat and cholesterol exacerbate the hy-
perlipoproteinemia found in the 2/2 animals, in agreement
Figure 3. Histological analysis of 
atherosclerotic lesions, skin, and
livers in 2/2, 3/3, or wild-type mice. 
(A–C) Cross-sections of the aortic 
sinus area stained with Sudan IV B 
(Fisher Scientific Co., Pittsburgh, 
PA), and counterstained with hema-
toxylin (1003). The micrographs 
are from (A) a 10-mo-old 2/2 female 
mouse maintained on a normal 
chow diet (the atherosclerotic 
plaque consists mainly of foam 
cells); (B) a 5-mo-old 2/2 female 
mouse fed an atherogenic diet for
3 mo (the advanced stage lesion in-
cludes foam cells, necrotic cores, 
cholesterol clefts, and fibrous caps); 
(C) a 5-mo-old 3/3 mouse fed the 
atherogenic diet for 3 mo (the lesion 
consists mainly of foam cells); (D) 
Severe xanthomatous lesion in the 
skin of a female 2/2 mouse fed the 
atherogenic diet for 3 mo (the lesion 
contains foam cells, cholesterol clefts, and neutrophils; hematoxylin and eosin, 4003); (E) liver section near a portal triad in a female 2/2 mouse 
fed the atherogenic diet for 3 mo showing relatively normal hepatocytes, intrasinusoidal foam cells (white arrowhead), and focal extramedullary 
hematopoiesis (arrow; hematoxylin and eosin, 8003); and (F) liver section near a portal triad in a female wild-type mouse fed the atherogenic 
diet for 3 mo, showing lipid-laden hepatocytes (arrow) together with anucleated and binucleated cells (hematoxylin and eosin, 8003).
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with the inverse observation that changing to a low-fat, low-
cholesterol diet alleviates the hyperlipidemia in most human
type III HLP patients (1). Furthermore, reduction of plasma
lipid levels and changes in lipoprotein profiles that occur in re-
sponse to clofibrate treatment are similar in humans and in the
2/2 mice.
The recapitulation in the 2/2 mice of the phenotypes seen
in human type III HLP makes these animals excellent models
in which to investigate environmental and genetic factors that
precipitate type III HLP and premature atherosclerosis in hu-
mans homozygous for the APOE*2 allele. The mice may also
help in determining the factor(s) that cause all 2/2 mice to de-
velop type III HLP, and may provide an insight into why only
5–10% of human 2/2 individuals develop the disease. The dif-
ferences between the apoE2 and apoE3 isoforms have a much
larger impact in mice than in most humans, possibly because
mice synthesize z 70% of their liver-derived VLDL as apoB48
particles (23, 24). Mice consequently depend more on apoE
for VLDL remnant clearance than do humans, in whom all the
VLDL particles from the liver contain apoB100 and can be
cleared via the LDL receptor independently of apoE.
Reduced plasma lipoprotein clearance due to hormonal,
dietary, and genetic changes that lower LDL receptor expres-
sion is thought to be a factor that triggers the type III HLP
phenotype in human patients (1). A similar reduction in clear-
ance because of a defective interaction between the mouse
LDL receptor and human apoE2 may account for the com-
plete penetrance of type III HLP phenotype in our 2/2 mice. In
contrast, interaction between human apoE3 and mouse recep-
tors is sufficient for the 3/3 mice to maintain normal plasma
lipid levels when they are fed regular chow. Nevertheless, the
3/3 mice are more susceptible to diet-induced hyperlipidemia
than are wild-type mice (10), suggesting that human apoE3 is
still not as good of a ligand to mouse receptor(s) as mouse
apoE protein. It is reasonable to expect that human apoE pro-
teins would not be as good ligands to mouse receptor(s) as
they are to human receptor(s), and further reduction of this in-
teraction after the Arg-158→Cys substitution in the apoE2
protein is the likely cause of the hyperlipidemia seen in the 2/2
mice, even on the regular chow. Detailed studies on ligand/re-
ceptor interactions in these mice are therefore indicated.
Spontaneous development of atherosclerosis in the 2/2 mice
fed regular chow, and its marked enhancement by feeding a
high-fat and high-cholesterol diet have much in common with
atherosclerosis that develops in mice that are unable to synthe-
size any apoE (13, 25, 26), although the mean cross-sectional
area of the atherosclerotic plaques in the 2/2 mice is approxi-
mately half that seen in age-matched apoE 2/2 mutants hav-
ing a similar genetic background, and the 2/2 plaques are less
mature. There is a clear hierarchy in the degree of atheroscle-
rosis among the four groups of animals that differ only at their
Apoe locus. The severity decreases in the order 2/2 . 2/2 .
3/3 . 1/1. The same order is observed when the circulation
times of the atherogenic particles (1/FCR) are compared
among these groups of animals. These observations conse-
quently support the generally accepted view that any prolon-
gation of the half-life of lipoproteins increases the likelihood
that they will be modified (e.g., by oxidation) into atherogenic
forms that are taken up by macrophages and smooth muscle
cells (27, 28).
We conclude that the 2/2 mice having the human apoE2
isoform expressed in a tissue-specific and physiological man-
ner, and their comparison with the 3/3 mice expressing the hu-
man apoE3 isoform, provide a powerful in vivo system for
studying the structural and functional differences between
these allelic forms of human apoE.
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